tiprankstipranks
Advertisement
Advertisement

GPCR Stock Latest News

Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
RatingsBuy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
19d ago
GPCR
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
20d ago
GPCR
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
PremiumRatings
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
20d ago
GPCR
Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
PremiumThe Fly
Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
20d ago
LLY
NVO
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
PremiumCompany Announcements
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
20d ago
8K
GPCR
Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study
PremiumThe FlyStructure Therapeutics: Aleniglipron achieved meaningful weight loss in study
20d ago
GPCR
Leveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
Premium
Ratings
Leveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
1M ago
GPCR
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
1M ago
GPCR
Structure Therapeutics price target lowered to $113 from $120 at Citizens
PremiumThe Fly
Structure Therapeutics price target lowered to $113 from $120 at Citizens
1M ago
GPCR
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
PremiumRatings
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
1M ago
GPCR
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
PremiumThe Fly
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
2M ago
V
CL
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
PremiumThe Fly
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
2M ago
GPCR
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
PremiumThe FlyStructure Therapeutics price target raised to $105 from $65 at JPMorgan
2M ago
GPCR
Structure Therapeutics price target raised to $140 from $90 at Guggenheim
Premium
The Fly
Structure Therapeutics price target raised to $140 from $90 at Guggenheim
3M ago
GPCR
Structure Therapeutics moved to Buy rating at Goldman Sachs
Premium
The Fly
Structure Therapeutics moved to Buy rating at Goldman Sachs
3M ago
LLY
GPCR
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
PremiumThe Fly
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
3M ago
LLY
NVO
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
PremiumThe Fly
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
3M ago
LLY
NVO
Structure Therapeutics rises 14.1%
PremiumThe Fly
Structure Therapeutics rises 14.1%
3M ago
GPCR
Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating
PremiumRatings
Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating
3M ago
GPCR
Structure Therapeutics inks major GLP-1 licensing deal
PremiumCompany AnnouncementsStructure Therapeutics inks major GLP-1 licensing deal
3M ago
8K
GPCR
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
4M ago
GPCR
Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
Premium
The Fly
Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
4M ago
GPCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >